APROS THERAPEUTICS, INC.
🇺🇸United States
A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Apros Therapeutics, Inc
- Target Recruit Count
- 11
- Registration Number
- NCT04645797
- Locations
- 🇺🇸
NEXT Oncology - San Antonio, San Antonio, Texas, United States
🇺🇸AdventHealth Orlando, Orlando, Florida, United States
🇺🇸NEXT Oncology - Austin, Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath